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ABSTRACT Harm reduction approaches endeavor to assist individuals with avoiding the
most detrimental consequences of risk taking behaviors, but limited research has
documented the outcomes of harm reduction substance abuse treatment. In total, 211
methamphetamine-using men who have sex with men (MSM) enrolled in two outcome
studies of substance abuse treatment programs that were implementing an evidence-
based, cognitive-behavioral intervention (i.e., the Matrix Model) from a harm reduction
perspective. Study 1 (N=123) examined changes in self-reported substance use,
Addiction Severity Index (ASI) composite scores, and HIV care indicators over a 12-
month follow-up. Study 2 (N=88) assessed changes in substance use, sexual risk taking,
and HIV care indicators over a 6-month follow-up. Participants in study 1 reported
reductions in cocaine/crack use as well as decreases in the ASI drug and employment
composite scores. Among HIV-positive participants in study 1 (n=75), 47 % initiated
or consistently utilized anti-retroviral therapy and this was paralleled by significant
increases in self-reported undetectable HIV viral load. Study 2 participants reported
reductions in methamphetamine use, erectile dysfunction medication use in combination
with other substances, and sexual risk-taking behavior while using methamphetamine.
Participants in both studies reported concurrent increases in marijuana use. Taken
together, these studies are among the first to observe that clients may reduce stimulant
use and concomitant sexual risk-taking behavior during harm reduction substance
abuse treatment. Randomized controlled trials are needed to examine the differential
effectiveness of harm reduction and abstinence-based approaches to substance abuse
treatment.
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INTRODUCTION
The use of stimulants (i.e., methamphetamine, cocaine, and crack) has negative
implications for HIV prevention and care. Among HIV-negative men who have
sex with men (MSM), those who use stimulants are more likely to report
engaging in sexual risk-taking behavior and are at elevated risk for HIV
seroconversion.1–3 It is also well-established that HIV-positive stimulant users
are more likely to experience difﬁculties with HIV disease management which
lead to elevated HIV viral load and potentially faster mortality.4–7 These
difﬁculties with HIV disease management often co-occur with HIV transmission
risk behavior, 8,9 which could contribute to the onward transmission of
medication-resistant strains of HIV.10,11
Behavioral treatments for stimulant dependence are moderately effective.1,12
Speciﬁcally, prior clinical research conducted by Shoptaw and colleagues
supports the efﬁcacy and effectiveness of a cognitive-behavioral treatment (i.e.,
the Matrix Model) that is culturally tailored for MSM.13,14 One randomized
controlled trial (RCT) with methamphetamine-using MSM observed that those
randomized to receive a culturally tailored Matrix Model intervention reported
greater reductions in unprotected receptive anal intercourse during the ﬁrst
4 weeks of treatment.13 In a second RCT, gay and bisexual men seeking
treatment for stimulant or alcohol abuse were randomized to receive this
culturally tailored Matrix Model intervention or gay-speciﬁc social support
therapy.14 Secondary analyses indicated that methamphetamine-using partici-
pants in the culturally tailored Matrix Model intervention reported greater
reductions in methamphetamine use over 1 year than those in gay-speciﬁc social
support therapy. Although ﬁndings support the clinical utility of the Matrix
Model with methamphetamine-using MSM, these RCTs focused on testing
abstinence-based approaches to treatment.
Harm reduction is a client-centered philosophy that engages clients in the
process of behavior change even if they are not motivated to abstain from
substance use or refrain from engaging in other risk-taking behaviors.15,16 In
the HIV prevention ﬁeld, harm reduction interventions such as needle
exchange are widely considered to be effective and have been successfully
implemented for decades.17 There is also some evidence to support the efﬁcacy
of other behavioral interventions that are implemented from a harm reduction
perspective. One recent RCT with HIV-positive, methamphetamine-using MSM
demonstrated that it is possible to promote sexual risk reduction without
decreasing methamphetamine use.18 The present studies documented the
outcomes of methamphetamine-using MSM who were receiving community-
based, harm reduction substance abuse treatment in order to determine
whether more deﬁnitive clinical research is warranted to examine the
effectiveness of this approach. The primary outcomes were self-reported
stimulant use and Addiction Severity Index (ASI) composite scores. Secondary
outcomes included: other substance use, sexual risk taking, anti-retroviral
therapy (ART) utilization, and self-reported undetectable HIV viral load. We
hypothesized that participants would report decreases in self-reported stimu-
lant use and ASI composite scores as well as concomitant reductions in sexual
risk taking and improvements in HIV care indicators.
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METHODS
The Stonewall Project Harm Reduction Treatment Model
The Stonewall Project model translates evidence-based interventions such as theMatrix
Model 13,14 into a clinical setting with a harm reduction focus. 19 Harm reduction is a
client-centered philosophy which does not assume that all individuals are ready, willing,
and able to pursue abstinence as a treatment goal. It also acknowledges that clients often
seek out substance abuse treatment services to address risky injection practices and
sexual risk-taking behavior, evenwhen they are not interested in changing substance use
patterns. Consistent with the harm reduction philosophy, the Stonewall Project model
assists clients with pursuing self-identiﬁed treatment goals as a means of engaging
individuals who might not otherwise initiate or remain in abstinence-based substance
abuse treatment. Regarding substance use, clients can choose to pursue abstinence as a
treatment goal, but strategies for managing substance use are often a primary focus of
treatment. Selected substance use management strategies in the Stonewall Project model
include: (1) transitioning to less potent modes of methamphetamine administration
(e.g., injecting to smoking, smoking to snorting); (2) promoting self-care strategies while
using methamphetamine (e.g., hydration, nutrition); and (3) delivering education about
safer injection practices with linkage to needle exchange and access to sterile syringes.
The Stonewall Project model also delivers sexual risk-reduction interventions to
promote condom use during anal sex as well as seroadaptive behaviors (e.g.,
serosorting, strategic positioning) for when clients choose not to use condoms.20
Clients are encouraged to develop plans for addressing barriers to sexual risk reduction,
even in the context of methamphetamine use. As part of the Stonewall Project model,
clients receive outpatient treatment that consists of weekly individual counseling, group
counseling twice a week, and psychotropic medications where appropriate. Unlike the
Matrix Model,13,14 clients are not asked to provide weekly urine samples to test for
recent stimulant use as part of their ongoing treatment. This 1-year outpatient drug
treatment program has been implemented for over 15 years by the community-based
substance abuse treatment programs that were the focus of the present outcome studies.
Treatment Outcome Study 1
Procedures. Study 1was conducted with two co-located outpatient programs that were
implementing the Stonewall Project model. One of the programs specialized in the
treatment of methamphetamine-usingMSM. The other served methamphetamine users
of any gender or sexual orientation, but only MSM clients were included in the present
study. All consecutive admissions to these programs from March 2005 to May 2008
were eligible. At the end of their program intake session, interested clients gave
permission for research staff to contact them (i.e., self-selection).
At the baseline assessment, research staff uninvolved with treatment services
completed the informed consent process and administered the ASI at the substance
abuse treatment site. At 6 and 12 months, the follow-up ASI was administered at the
substance abuse treatment site. In total, 132 methamphetamine-using MSM enrolled
in study 1, but nine were removed because they were also enrolled in study 2. Of the
123 unduplicated participants, 107 (87 %) and 98 (80 %) completed follow-up
assessments at 6 and 12 months, respectively. In total, 112 participants (91 %)
completed at least one follow-up assessment over the 12-month period. For their
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time and travel expenses, participants received US$10 at the baseline and 6-month
assessments as well as US$20 at the 12-month assessment. All participants signed a
separate authorization allowing research staff to extract data regarding treatment
utilization from clinical billing records. Study 1 procedures were approved by the
University of California, San Francisco Committee on Human Research.
Measures. Demographic information including items assessing sexual orientation
and gender identity was obtained from a modiﬁed demographics form for the ASI.
Among HIV-positive persons, self-reported ART utilization and undetectable viral
load were assessed via questionnaire. The ASI was administered at each study visit.
Responses were entered into ASI Drug Evaluation Network System (DENS)
software, which calculated composite scores.21 As part of the ASI, participants
reported the number of days that they had used speciﬁc substances in the past
30 days. Substances examined in this study included: methamphetamine, cocaine/
crack, marijuana, and drinking to intoxication.
Treatment Outcome Study 2
ProceduresMethamphetamine-using MSM were recruited from the outpatient
substance abuse treatment program in study 1 that is implementing the Stonewall
Project model exclusively with MSM from July 2010 to June 2012.22 Clients receiving
treatment at the Stonewall Project were eligible to enroll in study 2 up to: (1) 60 days
after treatment initiation; or (2) 60 days following re-initiation after more than 30 days
out of treatment (NCT 01129401). Clients who were interested in participating
completed a consent to contact form with their Stonewall Project counselor (i.e., self-
selection) that included permission to verify eligibility using treatment records.
After providing informed consent at the baseline assessment visit, participants
completed an assessment administered by a research assistant at the substance abuse
treatment site. This assessment included measures of self-reported substance use and
sexual risk taking that were administered using audio computer-assisted self-interviewing
(ACASI). Prior research has demonstrated that ACASI enhances the reliability of self-
report measures for substance use and sex risk.23,24 This assessment was re-administered
at 3 and 6 months follow-up at the substance abuse treatment site. Participants also
provided a urine sample for on-site toxicology screening for methamphetamine and
cocaine metabolites at each study assessment (Redicup®; Redwood Toxicology
Laboratory; Santa Rosa, CA). All study assessments were administered by a research
assistant who did not have a clinical role in the substance abuse treatment program.
Of the 88 participants enrolled in this treatment outcome study, 81 (92 %) and 79
(90 %) completed follow-up assessments at 3 and 6 months, respectively. In total, 85
participants (96 %) completed at least one follow-up assessment over the 6-month
period. At each study visit, participants were reimbursedwith a US$50 pre-loaded debit
card for their time and travel expenses. All participants signed a separate authorization
allowing research staff to extract data regarding treatment utilization from the clinical
records. Study 2 procedures were approved by the University of California, San
Francisco Committee on Human Research.
Measures. Demographic characteristics assessed by questionnaire included: age,
ethnicity, education, income, sexual orientation, gender identity, and HIV status.
Among HIV-positive persons, self-reported ART utilization and undetectable HIV viral
loadwere assessed at each study visit. Consistent with study 1, participants reported the
number of days they used speciﬁc substances in the past 30 days. Substances examined
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in this study included: methamphetamine, cocaine/crack, club drugs (i.e., ecstasy,
ketamine, or GHB), marijuana, binge drinking (i.e., six or more drinks on one
occasion), and erectile dysfunction (ED) medications in combination with other
substances (i.e., while “partying”). Participants also reported the longest number of
days in a row they used cocaine/crack or methamphetamine in the past 30 days.
Informed by previous research with methamphetamine users, 25 participants who
reported using any of these stimulants two or more days in a row were classiﬁed as
engaging in binge use (1) and compared to those who reported using 1 day at a time or
no use in the past 30 days (0). Participants who provided a urine sample that was
reactive for cocaine or methamphetamine metabolites (1) were compared to those who
provided a urine sample that was not positive for recent stimulant use (0).
Participants reported the number of anal sex partners in the past 3 months,
stratiﬁed by whether or not they were feeling the effects of methamphetamine during
sexual intercourse. For HIV-negative MSM, sexual risk-taking behavior was
operationalized as engaging in unprotected anal intercourse, irrespective of the
serostatus of the sexual partner(s). For HIV-positive MSM, sexual risk-taking
behavior was operationalized as unprotected anal intercourse with HIV-negative or
unknown serostatus partners. Estimates of any sexual risk-taking behavior were
calculated separately for receptive and insertive anal sex as a function of whether
participants were using methamphetamine to yield four separate indicators.
Statistical Analyses
Inferential analyses examining unadjusted change over time for each dependent variable
were performed with generalized estimating equations (GEE) in Stata using the binomial
distribution and logit link for binary dependent variables (e.g., ART, self-reported
undetectable HIV viral load), the multinomial distribution and cumulative logit link for
ordinal categorical dependent variables (i.e., ASI Alcohol andMedical composite scores),
the negative binomial distribution and log link for count dependent variables (e.g.,
number of methamphetamine days, number of anal sex partners), and the normal
distribution and identity link for continuous dependent variables (e.g. ASI Drug and
Employment composite scores). As recommended by Diggle, 26 the unstructured
covariance structure was used for binary, count, and continuous outcomes. For the
ordinal categorical dependent variables, the independent covariance structure was used.
Multiple imputation was employed to handle missing data for any models with
incomplete data due to both participant non-response (≤18 % in study 1, G2 % in
study 2) and loss to-follow-up (≤20 % in study 1, ≤10 % in study 2). Thus, the total
sample size is the same (N=123 for study 1,N=88 for study 2) in each reported analysis.
For binary outcomes, the odds ratio (OR) per unit change in the independent variable
is reported. For count outcomes, we report the incidence rate ratio (IRR) as well as the
percent change in the expected number of the outcome (Δ expected=100×(eB−1)). For
continuous outcomes, the raw change in the outcome per unit change in the independent
variable (B) is reported. Observed effect sizes were determined using Cohen’s d for
continuous and count dependent variables, Cohen’s h for binary dependent variables, and
the Uncertainty Coefﬁcient (c|r) for ordinal dependent variables.27–29
Dose–response analyses were performed only for dependent variables that exhibited
signiﬁcant change over time. To improve imputations by allowing information contained
in other non-missing variables to inform missing values, all dependent variables in the
dose–response analyses were used together to create 50 imputed datasets. Three different
dose variables were examined individually as correlates of change over time for each
signiﬁcant dependent variable: number of individual counseling sessions, number of
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group counseling sessions, and number of psychiatric sessions. The linearity assumption,
assessed via the cumulative sums of residuals method, 30 was not violated in any of the
models. To assess the associations of dose variables with outcomes over time, the
interaction of dose and timewas considered in amodel including bothmain effects. In the
two instances where the dose-time interaction was found signiﬁcant, the associations for
dose were calculated at the ﬁnal follow-up visit for that study.
RESULTS
Demographics and Health Status
Overall, participants in study 1 and study 2 were predominantly gay-identiﬁed,
Caucasian, middle-aged, and HIV-positive. As shown in Table 1, participants in
study 1 were younger, less likely to be prescribed ART at baseline, and less likely to
report undetectable HIV viral load at baseline. In study 1, 27 % of participants
TABLE 1 Comparison of demographic characteristics and health status at baseline
Study 1 Study 2
p value(N=123) (N=88)
N (%) N (%)
Gender – – 0.34
Male 121 (98.4) 88 (100.0)
Transgender (female to male) 2 (1.6) 0 (0.0)
Ethnicity – – 0.42
African American 9 (7.5) 10 (11.4)
Hispanic/Latino 26 (21.7) 12 (13.6)
Caucasian 79 (65.8) 59 (67.1)
Asian/Paciﬁc Islander 2 (1.7) 2 (2.3)
American Indian/Alaskan 1 (0.8) 0 (0.0)
Multicultural 3 (2.5) 5 (5.7)
Sexual orientation – – 0.11
Gay 106 (89.1) 85 (96.6)
Bisexual 10 (8.4) 2 (2.3)
Straight 1 (0.8) 1 (1.1)
Unsure 2 (1.7) 0 (0.0)
Education – – 0.10
Less than high school 11 (9.2) 3 (3.4)
High school graduate 19 (16.0) 13 (14.8)
Trade school or some college 44 (37.0) 34 (38.6)
College graduate 24 (20.2) 29 (33.0)
Graduate degree 21 (17.7) 9 (10.2)
Employed 34 (29.3) 25 (28.7) 0.93
Currently homeless 16 (13.2) 9 (10.2) 0.51
Ever incarcerated 34 (28.8) 24 (27.3) 0.81
HIV-positive 75 (63.6) 58 (65.9) 0.73
Currently prescribed anti-retroviral therapy 33 (44.0) 50 (86.2) G 0.0001
Self-reported undetectable HIV viral load 14 (18.6) 35 (60.3) G 0.0001
M (SD) M (SD)
Age 40.7 (7.5) 43.3 (9.0) 0.02
Years since HIV diagnosis – 10.8 (7.8) –
Self-reported T-helper (CD4+) count 444 (239) 527 (295) 0.11
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reported consistently utilizing ART while 20 % reported initiating and remaining on
ART during the 12-month follow-up period. In study 2, 75 % of participants
reported consistently utilizing ART while 2 % reported initiating and remaining on
ART following during the 6-month follow-up period.
Treatment Outcome Study 1 Analyses
As shown in Table 2, there were signiﬁcant reductions in cocaine/crack use days
between 6 and 12 months (IRR=0.54; 95 % conﬁdence Interval [CI]=0.32, 0.91;
pG0.05; Δ expected=−46.3 %). Participants also reported concurrent increases in
marijuana use days over the 12-month follow-up (IRR=1.46; 95 % CI=1.02, 2.09;
pG0.05; Δ expected=45.7 %). There were reductions in the ASI Drug composite
score over the 12-month follow-up (B=−0.03; 95 % CI=−0.05, −0.01; pG0.01),
indicating a decrease in drug use severity. There were also decreases in the ASI
Employment composite score over the 12-month follow-up (B=−0.04; 95 % CI=
−0.08, −0.01; pG0.05), representing an improvement in employment outcomes.
Lastly, more HIV-positive participants reported an undetectable viral load over the
12-month follow-up (OR=2.23; 95 % CI=1.12, 4.41; pG0.05).
For the crack/cocaine and marijuana use days as well as the ASI Drug composite
score, there were no signiﬁcant dose–response associations. A greater number of
individual counseling sessions (B=−0.001; 95 % CI=−0.002, −0.001; pG0.01) and
TABLE 2 Changes in outcomes over time for study 1 (N=123)
Baseline 6 months 12 months Effect size
M (SD) M (SD) M (SD) Cohen’s d
Methamphetamine-use days 4.85 (8.06) 4.57 (7.39) 4.92 (7.67) 0.01
Cocaine/crack-use days 1.67 (5.59) 2.05 (6.72) 1.06 (4.06) −0.12 *
Marijuana-use days 3.55 (7.72) 4.12 (8.38) 5.87 (9.95) 0.26 *
Drinking-to-intoxication days 1.22 (3.32) 0.94 (3.41) 1.18 (2.96) −0.01
ASI employment score 0.65 (0.31) 0.61 (0.31) 0.58 (0.29) −0.23 *
ASI drug score 0.19 (0.10) 0.16 (0.12) 0.17 (0.11) −0.19 **
ASI family/social score 0.20 (0.17) 0.16 (0.18) 0.17 (0.17) −0.18
ASI psychiatric score 0.36 (0.21) 0.37 (0.21) 0.35 (0.22) −0.05
N (%) N (%) N (%) Cohen’s h
ASI legal score 31 (26.7) 27 (26.0) 22 (22.9) −0.09
On ART (self-report) 33 (46.5) 40 (58.0) 29 (47.5) 0.02
Undetectable HIV viral load (self-report) 14 (20.0) 24 (42.1) 22 (37.3) 0.38 **
N (%) N (%) N (%) UC c|r
ASI medical score 0.0042
Zero 54 (48.2) 49 (46.8) 44 (47.3)
G=0.5† 30 (26.8) 31 (29.5) 19 (20.4)
90.5 28 (25.0) 25 (23.8) 30 (32.3)
ASI alcohol score 0.0013
Zero 45 (39.5) 42 (40.0) 38 (40.4)
G=0.128a 36 (31.6) 34 (32.4) 33 (35.1)
90.128 33 (29.0) 29 (27.6) 23 (24.5)
ART anti-retroviral therapy, UC c|r uncertainty coefﬁcient
*pG0.05; **pG0.01
aPseudo tertiles: 0 as the bottom category, and the second two categories bisect the remaining data
COMMUNITY-BASED HARM REDUCTION SUBSTANCE ABUSE TREATMENT 561
psychiatric sessions (B=−0.006; 95 % CI=−0.01, −0.003; pG0.01) attended were
associated with reductions in the ASI Employment composite score, which is
indicative of improved employment outcomes. For self-reported undetectable HIV
viral load, there was a signiﬁcant effect for the dose×time interaction for individual
counseling sessions, but the change in the outcome over time remains signiﬁcant
(OR=3.47; 95 % CI=1.37, 8.79; pG0.01) with the inclusion of the interaction. The
dose effect of the number of individual counseling sessions was not signiﬁcant at
12 months. These results using imputed data from study 1 were consistent with
sensitivity analyses using data that were not imputed.
Treatment Outcome Study 2 Analyses
As shown in Table 3, participants reported reductions in days of methamphetamine
use over the 6-month follow-up (IRR=0.71; 95 % CI=0.52, 0.96; pG0.05; Δ
expected=−29.4 %), increases in marijuana use through the 3-month follow-up
(IRR=1.36; 95 % CI=1.02, 1.82; pG0.05; Δ expected=36.1 %), and reductions in
ED medication use in combination with other substances over the 6-month follow-
up (IRR=0.37; 95 % CI=0.21, 0.66; pG0.01; Δ expected=−63.1 %). Participants
also reported concurrent reductions in the number of anal sex partners while using
methamphetamine over the 6-month follow-up (IRR=0.45; 95 % CI=0.27, 0.73;
pG0.01; Δ expected=−55.1 %) as well as decreased odds of any receptive sexual
risk taking while using methamphetamine over the 6-month follow-up (OR=0.53;
TABLE 3 Changes in outcomes over time for study 2 (N=88)
Baseline 3 months 6 months Effect size
M (SD) M (SD) M (SD) Cohen’s d
Meth-use days 5.23 (7.82) 5.06 (8.28) 3.57 (6.11) −0.24 *
Cocaine/crack-use days 0.77 (2.81) 0.58 (2.55) 0.58 (2.02) −0.08
Club-drug-use days 1.41 (4.41) 1.25 (4.37) 0.81 (2.71) −0.16
Marijuana-use days 4.59 (8.69) 6.14 (10.29) 5.35 (9.77) 0.08 *
Binge-drinking days 1.17 (2.96) 1.04 (2.84) 0.78 (1.92) −0.16
ED-medication-use-while-
“Partying” days
0.80 (2.50) 0.80 (3.56) 0.29 (0.64) −0.28 *
Number of anal sex partners
on meth
5.16 (10.33) 3.24 (9.83) 2.32 (6.66) −0.33 **
Number of anal sex partners
not on meth
2.06 (5.31) 1.58 (4.02) 1.56 (4.03) −0.04
N (%) N (%) N (%) Cohen’s h
Any binge stimulant use 43 (49) 35 (43) 34 (43) −0.13
Tox+ for stimulants 27 (32) 31 (40) 22 (32) 0.00
Any risky anal sex 35 (41) 29 (37) 29 (37) −0.15
Any risky RAS on meth 23 (26) 13 (17) 13 (17) −0.24 *
Any risky RAS not on meth 7 (8) 6 (8) 9 (12) 0.11
Any risky IAS on meth 17 (20) 12 (15) 9 (12) −0.22
Any risky IAS not on meth 9 (10) 6 (8) 6 (8) −0.09
On ART 50 (86) 41 (79) 42 (82) −0.10
Undetectable viral load (self-report) 35 (60) 35 (67) 37 (72) 0.26
Meth methamphetamine, ED erectile dysfunction, Tox+ reactive urine sample, RAS receptive anal sex, IAS
insertive anal sex, ART anti-retroviral therapy
*pG0.05, **pG0.01
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95 % CI=0.30, 0.94; pG0.05). Although the percentage of participants reporting
undetectable viral load increased over time, this effect was not statistically signiﬁcant
at 6 months (OR=1.60; 95 % CI=0.89, 2.86; p90.05). There was one signiﬁcant
dose–response association amongst the outcomes that exhibited change over time. Each
group counseling session attended was associated with a 2.4 % reduction in days of
methamphetamine use over the 6-month follow-up (IRR=0.98; 95 % CI=0.96, 0.99;
pG0.01; Δ expected=−2.37 %). These results using imputed data from study 2 were
consistent with sensitivity analyses using data that were not imputed.
DISCUSSION
To our knowledge, these studies are among the ﬁrst to document the outcomes of
community-based, outpatient substance abuse treatment that is being delivered from
a harm reduction perspective. In study 1, participants reported decreases in cocaine/
crack use as well as reductions in drug use severity and improvements in
employment status. Because harm reduction is a client-centered approach that
encourages individuals to identify and pursue their own treatment goals, it does not
require abstinence. Although we observed increases in marijuana use, participants in
study 1 also showed improvements in the drug use severity composite score of the
ASI which indexes polysubstance use, drug-related problems, and perceived need for
treatment. Improvements in employment status provide further support for
enhanced functioning in a key life domain, which for many participants was in the
context of ongoing substance use. Participants in study 2 reported reductions in the
frequency of methamphetamine use and concurrent increases in marijuana use, but
no measure of drug use severity was administered. Taken together, these results
provide preliminary support for the potential beneﬁts of harm reduction treatment
for assisting individuals with reducing stimulant use and minimizing its potential
negative consequences. Further clinical research in this area is warranted.
Substance abuse treatment can support HIV/AIDS prevention efforts, 31,32 and
study 2 observed reductions in HIV-related risk behaviors. Participants reported
reductions in the use of ED medications in combination with other substances. One
common side effect of stimulants such as methamphetamine is impaired erectile
functioning, 33 and men often use ED medications in combination with metham-
phetamine to achieve an erection, prolong sexual activity, or enhance sexual
pleasure.34 Because it is an independent risk factor for HIV seroconversion, 3,35
reductions in the use of ED medications in combination with other substances may
have important clinical implications. Consistent with prior clinical research, 13,14,18
participants also reported decreases in the number of anal sex partners while using
methamphetamine as well as decreased odds of engaging in any risky receptive anal
sex while using methamphetamine. Although more deﬁnitive clinical research is
clearly needed, ﬁndings highlight the potential beneﬁts of harm reduction substance
abuse treatment for decreasing the co-occurrence of methamphetamine use and
sexual risk taking among MSM.
Initiating and remaining on ART at higher T-helper (CD4+) counts can lead to
better health outcomes among HIV-positive persons as well as decrease onward HIV
transmission rates.36 In San Francisco, universal access to ART irrespective of CD4+
count was implemented in 2010, which led to reductions inHIV viral load among those
enrolled in HIV medical care.37 Consistent with these policy changes, the baseline
prevalence of ART utilization in study 2 (2010–2012) versus study 1 (2005–2008) was
signiﬁcantly higher (86 % vs. 47 %). Participants in study 1 reported increases in self-
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reported undetectable HIV viral load, which may be due in large part to the fact that
one-ﬁfth of those enrolled in this study initiated and remained on ART during the 12-
month follow-up period. In contrast, more than half of HIV-positive partici-
pants enrolled in study 2 (60 %) reported undetectable HIV viral load at
baseline. This restricted range combined with the fact that three-fourths of HIV-
positive participants consistently remained on ART during the 6-month follow-
up may account for the absence of a statistically signiﬁcant increase in self-
reported undetectable HIV viral load. The potential for substance abuse
treatment to optimize the effectiveness of HIV treatment as prevention remains
an important area for further clinical research.38
Findings from the present studies must be interpreted in context of some
important limitations. Because these studies documented the outcomes of
community-based substance abuse treatment programs, it was not ethical to
withhold treatment even temporarily in a wait-list control design. Although
reductions in stimulant use and concomitant sexual risk taking are largely
consistent with prior randomized controlled trials of the Matrix Model with
this population,13,14 it is not possible to determine whether observed changes
are attributable to regression to the mean without a comparison condition. It is
also noteworthy that reductions in the frequency of methamphetamine use in
study 2 were observed in the absence of concurrent decreases in the proportion
of participants providing a urine sample that was reactive for stimulants. Urine
biomarkers verify self-reported abstinence, but they do not index cumulative
exposure to stimulants over time. Further research is needed to examine
quantitative biomarkers (e.g., hair toxicology) that may better reﬂect frequency
and quantity of stimulant use over longer periods. Although there is some
limited support for the reliability and validity of self-reported undetectable HIV
viral load, 39 future research should also collect peripheral venous blood
samples to measure changes in HIV disease markers.
Harm reduction policies and programs are being implemented around the globe
to better meet the needs of those who are not ready, willing, or able to abstain from
substance use or refrain from engaging in other risk-taking behaviors.40 Random-
ized controlled trials are needed to examine the differential effectiveness of harm
reduction and abstinence-based approaches to substance abuse treatment. At the
same time, these studies are among the ﬁrst to observe that clients may reduce
stimulant use and concomitant sexual risk-taking behavior during harm reduction
substance abuse treatment.
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